These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27652260)

  • 21. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
    Che Y; Bo D; Lin X; Chen T; He T; Lin Y
    BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
    Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
    Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.
    Mpagama SG; Houpt ER; Stroup S; Kumburu H; Gratz J; Kibiki GS; Heysell SK
    BMC Infect Dis; 2013 Sep; 13():432. PubMed ID: 24034230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa.
    Said HM; Kock MM; Ismail NA; Mphahlele M; Baba K; Omar SV; Osman AG; Hoosen AA; Ehlers MM
    J Clin Microbiol; 2012 Sep; 50(9):2857-62. PubMed ID: 22649019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.
    Via LE; Cho SN; Hwang S; Bang H; Park SK; Kang HS; Jeon D; Min SY; Oh T; Kim Y; Kim YM; Rajan V; Wong SY; Shamputa IC; Carroll M; Goldfeder L; Lee SA; Holland SM; Eum S; Lee H; Barry CE
    J Clin Microbiol; 2010 Feb; 48(2):402-11. PubMed ID: 20032248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing prevalence and resistance patterns in children with drug-resistant tuberculosis in Mumbai.
    Shah I; Shah F
    Paediatr Int Child Health; 2017 May; 37(2):135-138. PubMed ID: 27686119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India.
    Paramasivan CN; Rehman F; Wares F; Sundar Mohan N; Sundar S; Devi S; Narayanan PR
    Int J Tuberc Lung Dis; 2010 Feb; 14(2):243-6. PubMed ID: 20074419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of the MTBDRsl assay in Georgia.
    Tukvadze N; Bablishvili N; Apsindzelashvili R; Blumberg HM; Kempker RR
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):233-9. PubMed ID: 24429319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco.
    Momen G; Aainouss A; Lamaammal A; Chettioui F; Blaghen M; Messoudi M; Belghmi K; Mouslim J; El Mzibri M; El Messaoudi MD; Khyatti M; Chaoui I
    Rev Inst Med Trop Sao Paulo; 2021; 63():e19. PubMed ID: 33787739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interruptions in supplies of second-line antituberculosis drugs--United States, 2005-2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(2):23-6. PubMed ID: 23325352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
    Al-Mutairi NM; Ahmad S; Mokaddas E
    Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.
    Zhang Z; Liu M; Wang Y; Pang Y; Kam KM; Zhao Y
    Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1959-66. PubMed ID: 24906439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of tuberculosis drug resistance among Tibetan refugees in India.
    Salvo F; Dorjee K; Dierberg K; Cronin W; Sadutshang TD; Migliori GB; Rodrigues C; Trentini F; Di Serio C; Chaisson R; Cirillo DM
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):655-62. PubMed ID: 24903934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain
    Timire C; Sandy C; Kumar AMV; Ngwenya M; Murwira B; Takarinda KC; Harries AD
    Int J Infect Dis; 2019 Apr; 81():236-243. PubMed ID: 30776546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.
    Cambau E; Viveiros M; Machado D; Raskine L; Ritter C; Tortoli E; Matthys V; Hoffner S; Richter E; Perez Del Molino ML; Cirillo DM; van Soolingen D; Böttger EC
    J Antimicrob Chemother; 2015 Mar; 70(3):686-96. PubMed ID: 25587993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.
    Heysell SK; Ahmed S; Ferdous SS; Khan MS; Rahman SM; Gratz J; Rahman MT; Mahmud AM; Houpt ER; Banu S
    PLoS One; 2015; 10(2):e0116795. PubMed ID: 25710516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant tuberculosis in Viet Nam.
    Dang TM; Nguyen TN; Wolbers M; Vo SK; Hoang TT; Nguyen HD; To MH; Vuong MB; Nguyen TP; Tran VQ; Nguyen TB; Vo TH; Nguyen TN; Dai VH; Phan TH; Nguyen HD; Farrar J; Caws M
    BMC Infect Dis; 2012 Mar; 12():49. PubMed ID: 22375832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.
    Cegielski JP; Dalton T; Yagui M; Wattanaamornkiet W; Volchenkov GV; Via LE; Van Der Walt M; Tupasi T; Smith SE; Odendaal R; Leimane V; Kvasnovsky C; Kuznetsova T; Kurbatova E; Kummik T; Kuksa L; Kliiman K; Kiryanova EV; Kim H; Kim CK; Kazennyy BY; Jou R; Huang WL; Ershova J; Erokhin VV; Diem L; Contreras C; Cho SN; Chernousova LN; Chen MP; Caoili JC; Bayona J; Akksilp S;
    Clin Infect Dis; 2014 Oct; 59(8):1049-63. PubMed ID: 25057101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.